INSIGHT BANK · 28 LIVING CARDS
Follow a question.
See what changes.
Evidence, technologies, people and the next test—connected, but not confused.
R&D Allocationv1 · 09.23
Who checks clinical AI decisions, and how is that supervision itself evaluated?
ARPA-H announced ADVOCATE development plans covering patient-facing AI, supervision, implementation and independent evaluation.
- ✓Program and awardsRecorded
- ?DevelopmentUnverified
- ?Clinical evaluationUnverified
- ?AuthorizationUnverified
New question openedPublished the analysis and recorded the next checks.
NEXT CHECKMissed errors, false alarms, appropriate clinical handoffs and evaluation in routine care.
R&D Allocationv1 · 09.29
Can cells retain their function through room-temperature storage and transport?
BoSS announced three development teams and independent testing by ATCC, with up to $87 million planned over four years.
- ✓Reports and agreements reviewedRecorded
- ?Further validationUnverified
- ?Adoption and benefitUnverified
New question openedRecorded a new question and follow-up checks from the approved manuscript.
NEXT CHECKStorage duration by cell type, recovered function and independent ATCC testing.
R&D Allocationv1 · 10.09
Who pays for the work of making AI-enabled trials viable, and what do they buy?
SURPASS calls for validation in real trials, with initial public support and a route to continuing operations. Participation does not establish an automatic allocation of drug development or commercial rights.
- ✓Reports and agreements reviewedRecorded
- ?Further validationUnverified
- ?Adoption and benefitUnverified
New question openedExamine continuing operations and payment for AI-enabled trials through the SURPASS solicitation.
NEXT CHECKSelected teams, trial execution, payment by later sponsors and terms for model and patient-data use.